EP Patent

EP2192892A2 — Pulsatile gastric retentive dosage forms

Assigned to Assertio Holdings Inc · Expires 2010-06-09 · 16y expired

What this patent protects

Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of th…

USPTO Abstract

Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as gastroesophageal reflux disease (GERD) and nocturnal acid breakthrough (NAB).

Drugs covered by this patent

Patent Metadata

Patent number
EP2192892A2
Jurisdiction
EP
Classification
—
Expires
2010-06-09
Drug substance claim
No
Drug product claim
No
Assignee
Assertio Holdings Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.